Advaxis Inc. (ADXS)

1.44 0 (0%)

IEX Real-Time Price

August 17, 2018 EST.

Nasdaq Global Select : Healthcare

Prev Close 1.44

Price Open 1.44

Volume: 109,172

Avg Volume: 756,354

Market Cap: 75.77M

P/E Ratio -0.68

52 Wk Range 1.15-7.4487



ADXS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
48.09M
2.52M
2.46
5.24%

2018-07-13
48.09M
2.24M
1.91
4.66%

2018-06-29
48.09M
2.75M
3.20
5.72%

2018-06-15
48.09M
4.1M
7.17
8.52%




ADXS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-06-07
Q2 2018
BTO
-0.41 (2)
-0.27
0.14

2018-03-12
Q1 2018
AMC
-0.58 (2)
-0.49
0.09

2017-12-20
Q4 2017
AMC
-0.55 (3)
-0.57
-0.02

2017-09-11
Q3 2017
N/A
-0.56 (2)
-0.80
-0.24

News

Your Daily Pharma Scoop: Redhill Zooms, FDA Nods Advaxis Ahead, Hologic Warned (2018-07-31 08:29 SeekingAlpha)

Stocks in News: RDHL, ADXS RedHill's RHB-104 successful in late-stage Crohn's study; shares up 40% premarket Discussion : RedHill Biopharmas ( RDHL ) RB-104 succeeds in Phase 3 clinical trial on Crohn's disease patients. Primary endpoint of remission at 26th week against the d…

 

3 Things In Biotech, July 31: Progenics Bucks The Doubters (2018-07-31 08:00 SeekingAlpha)

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Progenics comes through with its first anticancer approval Company : Progenics Pharmac…

 

Biotech Analysis Central Pharma News: Celgene's Earnings, Achaogen Cuts Staff, Advaxis Receives IND Clearance (2018-07-31 04:58 SeekingAlpha)

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Celgene's Profits Reach Above Expectations For The Second-Quarter News: Recently, Celgene ( CELG ) reported profit that exceeded analysts' expectat…

 


Statistics

Shares Outstanding: 52.62M

Top 15 Institution Percent: 32.60

Price To Sales: 13.61

Price To Book: 1.67

Revenue: 4.81M

Gross Profit: N/A

Cash: 159.70M

Debt: N/A

Return On Assets: -82.73

Return On Equity: -130.76

Profit Margin: N/A

Price History

Beta: 2.25

50-day Moving Avg: 1.53

200-day Moving Avg: 2.20

YTD Change: -53.55

5-day Change: -2.70

1-month Change: 2.13

3-month Change: -18.64

6-month Change: -44.40

1-year Change: -76.28

Revenue Per Share: 0.00

Revenue Per Employee: 44582.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Advaxis Inc.

Exchange: Nasdaq Global Select

Industry: Biotechnology

Sector: Healthcare

Website: http://www.advaxis.com

Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies.